Heptares

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Leave a Comment / Medicine / By

Sosei Group Corporation has translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK, and KU Leuven, Belgium. Sosei Heptares focuses on the design and development of structure-based drugs (SBDDs) focused on G-protein-coupled receptors (GPCRs). The goal of the agreements is to apply the innovative technologies and research …

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders Read More »

Sosei Heptares Enters R&D Agreements with Oxford University and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

Sosei Heptares Enters R&D Agreements with Oxford University and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

Leave a Comment / Medicine / By

Sosei Group Company The agreements build on Sosei Heptares’ target identification and validation strategy and translational medicine approach to drug discovery, enabling the company to rapidly prioritize disease-relevant GPCR targets for the structure-based drug design TOKYO and CAMBRIDGE, United Kingdom, 08 Dec. 11, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE: 4565), the …

Sosei Heptares Enters R&D Agreements with Oxford University and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders Read More »